• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CVO
Click for more information
0.00% $1.95

COVER-MORE GROUP LIMITED

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CVO
Ann: REMOVAL FROM OFFICIAL LIST 		18/04/17 0 493
18/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  493 
CVO
News: CVO Zurich Insurance says completes acquisition of Cover-More 		13/04/17 0 478
13/04/17 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  478 
CVO
Ann: Initial Director's Interest Notice 		13/04/17 0 307
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  307 
CVO
Ann: Initial Director's Interest Notice 		13/04/17 0 200
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  200 
CVO
Ann: Final Director's Interest Notice 		13/04/17 0 201
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  201 
CVO
Ann: Final Director's Interest Notice 		13/04/17 0 185
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  185 
CVO
Ann: Final Director's Interest Notice 		13/04/17 0 188
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  188 
CVO
Ann: Final Director's Interest Notice 		13/04/17 0 151
13/04/17 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  151 

See All Discussions arrow Created with Sketch.

Top Stories

The winners & losers on market if negative gearing were gone

Removing negative gearing would likely cause a seismic shift in investor behaviour. If that advantage were taken away, more investors might start eyeing the stock market...
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico? De Grey Mining on Friday denied reports that it's received a takeover offer from Canada-based Agnico Eagle.
The market's shrugged at China's stimulus measures all year. Why is this one different? If you've been following the Chinese economy this year, you'd know that the country has been trying to stimulate all year.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.